ARTHUR-D.-LITTLE
11.1.2021 15:33:34 CET | Business Wire | Press release
Arthur D. Little (ADL) today announced that it has been awarded multiple high impact projects by the European Space Agency (ESA) to help identify the most promising services for next generation satellite communication (SatCom) infrastructure. ADL will conduct a major consultation process with key members of the transport, energy, infrastructure and media industries, plus stakeholders in law enforcement and emergency services, to identify and assess potential applications and services that could be delivered via satellite in the next decade.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005719/en/
ADL will be responsible for four studies in total. Three of the studies are part of the Advanced Research in Telecommunications Systems (ARTES) 4.0 Strategic Programme Line “Space Systems for Safety and Security” (4S), and are supported by the Italian Space Agency:
- Safety of Future Transport
- Safeguarding Essential Services
- Satellite Applications for Public Safety
As part of its ‘Open Consulting’ approach, ADL will conduct these studies with input from Distretto Tecnologico Aerospaziale (DTA).
The fourth study is an ARTES4.0 Business Applications Feasibility Study and is supported by the Norwegian Space Agency:
- Port of the Future
ADL will conduct this study in collaboration with Marlink and CLS.
With society and the economy dependent on telecommunications networks, the aim of 4S is to support the development of secure SatCom systems to both improve digital infrastructure resilience across Europe and the rest of the world, and provide innovative services and solutions. As terrestrial networks become increasingly vulnerable to disruption and attack, integrating next generation SatCom systems with the existing digital infrastructure can help make these networks more resilient and secure.
The Safety of Future Transport study will focus on how next generation SatCom solutions can increase safety and efficiency in the fast-evolving aviation, maritime and railway sectors, with potential applications relating to unmanned aircraft and ships, and automated traffic management systems. Safeguarding Essential Services will focus on how SatCom can help protect critical infrastructure such as energy utilities as well as public media. Satellite Applications for Public Safety will focus on how SatCom can supplement and support existing Public Protection and Disaster Relief (PPDR) networks used by first responders such as the police, fire brigade, health services and search & rescue.
The Port of the Future study will assess the technical feasibility and economic viability of new Earth observation and SatCom-based services for the port industry, focusing not only on operations of the port itself, but also on monitoring their environmental impact in terms of air and water quality.
Francesco Marsella, Managing Partner and Global S&O Practice Leader at ADL , comments: "SatCom has an increasingly vital role to play in protecting our society and making its infrastructure more secure and resilient. As terrestrial networks become more prone to failure, whether due to natural disaster or cyberattack, SatComs can support and maintain European telecoms systems. These studies will be key to developing existing satellite systems and identifying the services of the future.”
Lars Thurmann-Moe, Managing Partner, ADL Norway , comments: “It is not always appreciated quite how important the maritime sector remains, with the great majority of goods still transported by sea. SatCom is already central to modern maritime operations in terms of communication and navigation, but there is still so much more that can be done to improve these operations, and also reduce the industry’s environmental footprint – for instance, helping to quickly pinpoint oil spillages.”
Matteo Ainardi, Head of the Aerospace & Defense Competence Center at ADL , comments: "The satellite industry is today being disrupted by the introduction of new technologies such as large scale low earth orbit (LEO) constellations, reusable launchers and phased-array antennas. It is the right time to assess the evolving demand for SatCom solutions, and develop a next generation SatCom capability that can leverage these major technological breakthroughs to the benefit of the European society and economy. ADL is highly involved in the commercial space sector – as such, we are very pleased to be working with ESA on these studies, and look forward to applying our industry expertise to help define the SatCom-based services and applications of the future.”
To find out more about Arthur D. Little’s work in the space industry, please visit www.adlittle.com/en/industries/aerospace-defense
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005719/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
